Keyphrases
Anti-inflammatory Effect
14%
Attentional Deficits
14%
Axon
14%
Axonal Loss
14%
Brain Injury
14%
Cancer Therapeutics
14%
Cell Death
28%
Clinical Trials
14%
Clinically Meaningful Outcomes
14%
Clinically Significant
14%
Cognitive Function
14%
Cognitive Impairment
14%
Controlled Cortical Impact
100%
Corpus Callosum
14%
Dentate Gyrus
28%
Functional Improvement
14%
Functional Outcome
100%
Functional Recovery
14%
Inflammation Response
14%
Inflammatory Response
28%
Lesion Margin
14%
Long-term Recovery
14%
Loss Recovery
14%
Microglial Activation
100%
Motor Deficits
14%
Motor Function
14%
Motor Impairment
14%
PARP Inhibitor (PARPi)
28%
Perilesional
14%
Reactive Astrocytosis
14%
Therapeutic Window
14%
Traumatic Brain Injury
100%
Treatment Delay
14%
Treatment Duration
14%
Veliparib
100%
Window of Opportunity
14%
Medicine and Dentistry
Antiinflammatory Activity
16%
Astrocytosis
16%
Axon
16%
Cell Death
33%
Clinical Trial
16%
Cognitive Defect
16%
Corpus Callosum
16%
Dentate Gyrus
33%
Malignant Neoplasm
16%
Motor Performance
16%
PARP Inhibitor
33%
Serositis
50%
Stereotypic Movement Disorder
16%
Therapeutic Window
16%
Translating (Language)
16%
Traumatic Brain Injury
100%
Veliparib
100%
Neuroscience
Anti-Inflammatory
16%
Axon
16%
Brain Trauma
16%
Cell Death
33%
Cognitive Disorders
16%
Corpus Callosum
16%
Dentate Gyrus
33%
Neurotrauma
100%
PARP Inhibitor
33%
Stereotypic Movement Disorder
16%
Traumatic Brain Injury
100%
Veliparib
100%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinflammatory Activity
16%
Astrocytosis
16%
Clinical Trial
16%
Cognitive Defect
16%
Inflammation
50%
Malignant Neoplasm
16%
Motor Dysfunction
16%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
Therapeutic Window
16%
Traumatic Brain Injury
100%
Veliparib
100%